CLS B Stock Overview
Engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Clinical Laserthermia Systems AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 5.42 |
52 Week High | SEK 43.60 |
52 Week Low | SEK 4.70 |
Beta | 0.36 |
11 Month Change | -12.43% |
3 Month Change | -63.22% |
1 Year Change | -78.67% |
33 Year Change | -99.29% |
5 Year Change | -99.75% |
Change since IPO | -99.62% |
Recent News & Updates
Shareholder Returns
CLS B | SE Medical Equipment | SE Market | |
---|---|---|---|
7D | -6.6% | -4.0% | -4.3% |
1Y | -78.7% | -0.002% | 12.6% |
Return vs Industry: CLS B underperformed the Swedish Medical Equipment industry which returned -0% over the past year.
Return vs Market: CLS B underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
CLS B volatility | |
---|---|
CLS B Average Weekly Movement | 20.1% |
Medical Equipment Industry Average Movement | 7.1% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CLS B's share price has been volatile over the past 3 months.
Volatility Over Time: CLS B's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 17 | Dan Mogren | www.clinicallaser.se |
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment.
Clinical Laserthermia Systems AB (publ) Fundamentals Summary
CLS B fundamental statistics | |
---|---|
Market cap | SEK 75.51m |
Earnings (TTM) | -SEK 70.90m |
Revenue (TTM) | SEK 10.83m |
7.0x
P/S Ratio-1.1x
P/E RatioIs CLS B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CLS B income statement (TTM) | |
---|---|
Revenue | SEK 10.83m |
Cost of Revenue | SEK 8.46m |
Gross Profit | SEK 2.37m |
Other Expenses | SEK 73.27m |
Earnings | -SEK 70.90m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
Earnings per share (EPS) | -5.09 |
Gross Margin | 21.88% |
Net Profit Margin | -654.91% |
Debt/Equity Ratio | 3.0% |
How did CLS B perform over the long term?
See historical performance and comparison